United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
United Therapeutics will present two oral and five poster presentations at the CHEST 2026 Annual Meeting (October 18-21, Phoenix) spanning its PAH, PH-ILD, and IPF portfolio. A pre-specified subgroup analysis of the phase 3 ADVANCE OUTCOMES study showed ralinepag reduced clinical worsening risk in PAH patients regardless of baseline risk criteria, and a post-hoc TETON-2 analysis showed nebulized treprostinil significantly reduced disease progression events in IPF patients. The FDA has accepted both the ralinepag NDA for PAH and the nebulized treprostinil sNDA for IPF; both assets remain investigational.
Key figures
- Drug Name
- ralinepag; nebulized treprostinil
- Phase Of Trial
- Phase 3
- Trials
- ["ADVANCE OUTCOMES","TETON-2","PHINDER","DeciPHer-ILD"]
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.